FCCC Program Consulting
Share the Fox Chase team's experience.
Read more »
A Century of Excellence
Discover the history of one of the nation's first cancer hospitals.
Read more »
Steven J. Cohen, MD
Chief, Gastrointestinal Medical Oncology
Medical Director, Medical Oncology, Fox Chase Cancer Center Partners
Co-Leader, Gastrointestinal Cancer Service Line
Dr. Cohen is a medical oncologist specializing in the treatment of gastrointestinal cancers. He holds several leadership roles at Fox Chase Cancer Center including Medical Director, Medical Oncology, for the Partners program. He oversees the Partners research program and is an active Principal Investigator at Fox Chase Cancer Center.
BA, (Psychology), Cornell University, Ithaca, New York
Doctor of Medicine, State University of New York at Stony Brook, Stony Brook, New York
American Society of Clinical Oncology
Eastern Cooperative Oncology Group
Journal of Gastrointestinal Cancer, Editorial Board
Member, National Comprehensive Cancer Network Pancreatic Adenocarcinoma Guidelines Committee
American Board of Internal Medicine, Medical Oncology
Commonwealth of Pennsylvania, Medical License
Drug Enforcement Agency License
NCI Clinical Investigator Team Leadership Award
2012-2013 ASCO Leadership Development Program
Dr. Cohen is a medical oncologist specializing in the treatment of gastrointestinal malignancies, with a particular focus on pancreatic, esophageal, colorectal, liver, and stomach cancers. His research interests include discovering new treatments through innovative clinical trials for patients with the above cancers.
Selected Recent Publications:
- Cohen SJ, Zalupski MM, Modiano MR, Conkling P, Patt YZ, Davis P, Dorr RT, Boytim ML, Hersh EM. A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer. Cancer Chemother Pharmacol, 2010 Jul;66(2):287-94.
- Cohen SJ, Punt CJA, Iannoti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse M, Mitchell E, Miller MC, Doyle GV, Tissing H, Terstappen LWMM, Meropol NJ. The Relationship of Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in Patients with Metastatic Colorectal Cancer. J Clin Oncol, 26(19):3213-21, 2008.
- O'Grady MA, Slater E, Sigurdson ER, Meropol NJ , Weinstein A, Lusch CJ, Sein E, Keeley P, Miller B, Engstrom PF, Cohen SJ. Assessing Compliance with National Comprehensive Cancer Network (NCCN) guidelines for elderly patients with stage III colon cancer: The Fox Chase Cancer Center Partners' Initiative. Clinical Colorectal Cancer, 2011 Jun;10(2):113-6. Epub 2011 Apr 22.
- Dotan E, Meropol NJ, Burtness B, Denlinger CS, Lee J, Mintzer D, Zhu F, Ruth K, Tuttle H, Sylvester J, Cohen SJ. A Phase II Study of Capecitabine, Oxaliplatin, and Cetuximab with or Without Bevacizumab as Frontline Therapy for Metastatic Colorectal Cancer. A Fox Chase Extramural Research Study. J Gastrointest Cancer. 2012 Feb 1.
- Dotan E, Meropol NJ, Zhu F, Zambito F, Bove B, Cai KQ, Godwin AK, Golemis EA, Astsaturov I, Cohen SJ. Relationship of increased aurora kinase A gene copy number, prognosis and response to chemotherapy in patients with metastatic colorectal cancer. Br J Cancer. 2012 Jan 12.